- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03466294
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject must have confirmation of non-APL AML by WHO criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factors
- Subject must have received no prior treatment for AML; hydroxyurea is not considered a treatment and is allowed
- Subject must be ≥ 60 years of age
- Subject must have a projected life expectancy of at least 12 weeks
- Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of ≤2
- Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula
Subject must have adequate liver function as demonstrated by:
- aspartate aminotransferase (AST) ≤ 3.0 × ULN*
- alanine aminotransferase (ALT) ≤ 3.0 × ULN*
bilirubin ≤ 3.0 × ULN, unless due to Gilbert's syndrome*
- Unless considered due to leukemic organ involvement
- Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug.
Female subjects must be either:
- Postmenopausal; defined as Age > 55 years with no menses for 12 or more months without an alternative medical cause; OR
- Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
- Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
Exclusion Criteria:
- Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agent either conventional or experimental for myelodysplastic syndrome (MDS) or AML
- Subject has acute promyelocytic leukemia
- Subject has known active CNS involvement from AML
- Subject is known to be positive for HIV. HIV testing is not required
- Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate
- Subject has received anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within 5 half-lives prior to first dose of study drug
- Subject has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within 30 days prior to first dose of study drug
Subject has received the following within 7 days prior to the first dose of the study drug:
- Steroid therapy for anti-neoplastic intent;
- Strong and Moderate CYP3A inhibitors (see Appendix A for examples)
- Strong and Moderate CYP3A inducers (see Appendix A for examples)
- Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment
Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:
- New York Heart Association heart failure > class 2
- Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia
- Subject has a malabsorption syndrome or other condition that precludes enteral route of administration
- Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)
Subject has a history of other malignancies prior to study entry, with the exception of:
- Adequately treated in situ carcinoma of the breast or cervix uteri
- Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
- Prostate cancer with no plans for therapy of any kind
- Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
- Subject has a white blood cell count > 25 × 109/L. Note: hydroxyurea is permitted to meet this criteria
- Any subject who is a candidate for intensive induction therapy and agrees to receive this therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Azacitidine and Venetoclax
On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days.
Azacitidine doses will be given in subsequent cycles for patients who do not achieve response.
Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1.
Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
|
Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response.
Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response to azacitidine and venetoclax treatment
Time Frame: From the first day a response is documented to the first day of disease progression
|
Determine how long responses last in patients treated with azacitidine and venetoclax followed by venetoclax maintenance treatment
|
From the first day a response is documented to the first day of disease progression
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Minimal Residual Disease (MRD) negative composite responses within the "induction phase" of azacitidine and venetoclax
Time Frame: From Day 28, the first day a response is documented to end of cycle bone marrow biopsies, through 5 years
|
The number of patients who achieve an MRD negative composite response
|
From Day 28, the first day a response is documented to end of cycle bone marrow biopsies, through 5 years
|
The time needed to achieve an MRD negative composite response
Time Frame: From first dose of treatment to first day response is documented by bone marrow biopsy
|
The median number of days that have elapsed leading to an MRD negative composite response
|
From first dose of treatment to first day response is documented by bone marrow biopsy
|
The one-year overall survival (OS) of older, newly diagnosed AML patients treated with "induction phase" of azacitidine with venetoclax followed by a maintenance Phase of venetoclax alone.
Time Frame: From date of study enrollment to one year after enrollment
|
The number of patients who survive to one year after date of study enrollment
|
From date of study enrollment to one year after enrollment
|
Hematologic Toxicity as defined by the 2017 ELN AML Recommendations
Time Frame: From the day venetoclax with azacitidine is administered to the end of maintenance venetoclax alone, up to one year
|
Hematologic toxicities will be measured by incidence of febrile neutropenia, ≥ grade 2 bleeding complications and number of transfusions received
|
From the day venetoclax with azacitidine is administered to the end of maintenance venetoclax alone, up to one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dan Pollyea, University of Colorado, Denver
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-7821.cc
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Azacitidine and Venetoclax
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
The First Affiliated Hospital of Soochow UniversityNorthern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaboratorsRecruitingRecruiting | T-cell Acute Lymphoblastic LeukemiaChina
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | NPM1 MutationItaly
-
Genfleet Therapeutics (Shanghai) Inc.Sellas Life Sciences GroupRecruitingHematologic MalignanciesChina, United States
-
Novartis PharmaceuticalsCompletedMyelodysplastic Syndrome (MDS)France, Spain, Belgium, Italy, Greece, Hungary, Germany
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaboratorsRecruiting
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Dongguan People's Hospital; Huizhou Municipal Central... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | Refractory Leukemia | Relapsed Adult AMLChina
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Stem Cell Transplant ComplicationsChina
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid LeukemiaItaly, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States